Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship - PA: Biomedical / Clinical HIV/AIDS Research

University of Toronto

$135,000.00

Characterization of a human retroviral restriction factor and its viral antagonist

EF 2010-11

Résumé
HIV-1 poses a critical threat to humankind all around the world. The Joint United Nations program on HIV/AIDS and the World Health Organization recognize HIV-1 as a global pandemic, with an estimate of ~2.5 million new HIV-1 infections each year. In 2005, 16-40% of new HIV-1 infections were resistant to one or more existing forms of antiviral therapy. There is pressing need for radically different therapeutics. The infectivity of HIV-1 is largely influenced by a protein called Viral Infectivity Factor (VIF). This proposed research aims to uncover how VIF counteracts proteins of humans' immune system, specifically the apolipoprotein B mRNA-editing catalytic polypeptide 3 family of proteins. Our findings will drive the development of novel therapeutic agents that will hinder the spread of HIV among individuals, as well as the progression of HIV to AIDS in infected patients.
Programme
Fellowship - PA: Biomedical / Clinical HIV/AIDS Research
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
216077
Name
Siu Karen K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Characterization of a human retroviral restriction factor and its viral antagonist
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
Fellowship - PA: Biomedical / Clinical HIV/AIDS Research
Keyworddelim
Aids; Hiv; Human Innate Immune System; Novel Antiviral Therapeutics; Restriction Factors; Viral Infectivity Factor; Viral Pathogenesis
Abstract
HIV-1 poses a critical threat to humankind all around the world. The Joint United Nations program on HIV/AIDS and the World Health Organization recognize HIV-1 as a global pandemic, with an estimate of ~2.5 million new HIV-1 infections each year. In 2005, 16-40% of new HIV-1 infections were resistant to one or more existing forms of antiviral therapy. There is pressing need for radically different therapeutics. The infectivity of HIV-1 is largely influenced by a protein called Viral Infectivity Factor (VIF). This proposed research aims to uncover how VIF counteracts proteins of humans' immune system, specifically the apolipoprotein B mRNA-editing catalytic polypeptide 3 family of proteins. Our findings will drive the development of novel therapeutic agents that will hinder the spread of HIV among individuals, as well as the progression of HIV to AIDS in infected patients.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Siu, Karen K
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~